Search

Your search keyword '"Hameed, Meera"' showing total 977 results
Start Over Author "Hameed, Meera"
977 results on '"Hameed, Meera"'

101. Bone and Joints

Author

Khurana, Jasvir S., Parajuli, Shobha, Hameed, Meera, Cheng, Liang, editor, and Bostwick, David G., editor

Published
2016
Full Text
View/download PDF

102. BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology

Author

Chiang, Sarah, Lee, Cheng-Han, Stewart, Colin J R, Oliva, Esther, Hoang, Lien N, Ali, Rola H, Hensley, Martee L, Arias-Stella, Javier A, III, Frosina, Denise, Jungbluth, Achim A, Benayed, Ryma, Ladanyi, Marc, Hameed, Meera, Wang, Lu, Kao, Yu-Chien, Antonescu, Cristina R, and Soslow, Robert A

Published
2017
Full Text
View/download PDF

109. Abstract 3556: Assessing patterns of genomic instability in recurrent osteosarcoma

Author

Kinnaman, Michael David, primary, Zaccaria, Simone, additional, Makohon-Moore, Alvin, additional, Gundem, Gunes, additional, Ossa, Juan E. Arango, additional, Dela Cruz, Filemon S., additional, Meyers, Paul A., additional, Hameed, Meera, additional, Tap, William D., additional, Bender, Julia Lynne Glade, additional, Papaemmanuil, Elli, additional, Kung, Andrew, additional, and Donahue, Christine Iacobuzio, additional

Published
2023
Full Text
View/download PDF

110. Data from Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma

Author

Dermawan, Josephine Kam Tai, primary, Nafa, Khedoujia, primary, Mohanty, Abhinita, primary, Xu, Yingjuan, primary, Rijo, Ivelise, primary, Casanova, Jacklyn, primary, Villafania, Liliana, primary, Benhamida, Jamal, primary, Kelly, Ciara M., primary, Tap, William D., primary, Boland, Patrick J., primary, Fabbri, Nicola, primary, Healey, John H., primary, Ladanyi, Marc, primary, Lu, Chao, primary, and Hameed, Meera, primary

Published
2023
Full Text
View/download PDF

111. Supplementary Table TS1 from Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma

Author

Dermawan, Josephine Kam Tai, primary, Nafa, Khedoujia, primary, Mohanty, Abhinita, primary, Xu, Yingjuan, primary, Rijo, Ivelise, primary, Casanova, Jacklyn, primary, Villafania, Liliana, primary, Benhamida, Jamal, primary, Kelly, Ciara M., primary, Tap, William D., primary, Boland, Patrick J., primary, Fabbri, Nicola, primary, Healey, John H., primary, Ladanyi, Marc, primary, Lu, Chao, primary, and Hameed, Meera, primary

Published
2023
Full Text
View/download PDF

112. Supplementary Figure FS1 from Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma

Author

Dermawan, Josephine Kam Tai, primary, Nafa, Khedoujia, primary, Mohanty, Abhinita, primary, Xu, Yingjuan, primary, Rijo, Ivelise, primary, Casanova, Jacklyn, primary, Villafania, Liliana, primary, Benhamida, Jamal, primary, Kelly, Ciara M., primary, Tap, William D., primary, Boland, Patrick J., primary, Fabbri, Nicola, primary, Healey, John H., primary, Ladanyi, Marc, primary, Lu, Chao, primary, and Hameed, Meera, primary

Published
2023
Full Text
View/download PDF

113. Supplementary Data #1 from Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma

Author

Zhu, Guo Gord, primary, Nafa, Khedoudja, primary, Agaram, Narasimhan, primary, Zehir, Ahmet, primary, Benayed, Ryma, primary, Sadowska, Justyna, primary, Borsu, Laetitia, primary, Kelly, Ciara, primary, Tap, William D., primary, Fabbri, Nicola, primary, Athanasian, Edward, primary, Boland, Patrick J., primary, Healey, John H., primary, Berger, Michael F., primary, Ladanyi, Marc, primary, and Hameed, Meera, primary

Published
2023
Full Text
View/download PDF

114. Supplementary Data from A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma

Author

Gounder, Mrinal M., primary, Rosenbaum, Evan, primary, Wu, Nian, primary, Dickson, Mark A., primary, Sheikh, Tahir N., primary, D'Angelo, Sandra P., primary, Chi, Ping, primary, Keohan, Mary Lou, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Agaram, Narasimhan, primary, Hameed, Meera R., primary, Martindale, Moriah, primary, Lefkowitz, Robert A., primary, Crago, Aimee M., primary, Singer, Sam, primary, Tap, William D., primary, Takebe, Naoko, primary, Qin, Li-Xuan, primary, and Schwartz, Gary K., primary

Published
2023
Full Text
View/download PDF

116. Supplementary Data #3 from Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma

Author

Zhu, Guo Gord, primary, Nafa, Khedoudja, primary, Agaram, Narasimhan, primary, Zehir, Ahmet, primary, Benayed, Ryma, primary, Sadowska, Justyna, primary, Borsu, Laetitia, primary, Kelly, Ciara, primary, Tap, William D., primary, Fabbri, Nicola, primary, Athanasian, Edward, primary, Boland, Patrick J., primary, Healey, John H., primary, Berger, Michael F., primary, Ladanyi, Marc, primary, and Hameed, Meera, primary

Published
2023
Full Text
View/download PDF

117. Supplementary Data from Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations

Author

Suehara, Yoshiyuki, primary, Alex, Deepu, primary, Bowman, Anita, primary, Middha, Sumit, primary, Zehir, Ahmet, primary, Chakravarty, Debyani, primary, Wang, Lu, primary, Jour, George, primary, Nafa, Khedoudja, primary, Hayashi, Takuo, primary, Jungbluth, Achim A., primary, Frosina, Denise, primary, Slotkin, Emily, primary, Shukla, Neerav, primary, Meyers, Paul, primary, Healey, John H., primary, Hameed, Meera, primary, and Ladanyi, Marc, primary

Published
2023
Full Text
View/download PDF

118. Data from A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma

Author

Gounder, Mrinal M., primary, Rosenbaum, Evan, primary, Wu, Nian, primary, Dickson, Mark A., primary, Sheikh, Tahir N., primary, D'Angelo, Sandra P., primary, Chi, Ping, primary, Keohan, Mary Lou, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Agaram, Narasimhan, primary, Hameed, Meera R., primary, Martindale, Moriah, primary, Lefkowitz, Robert A., primary, Crago, Aimee M., primary, Singer, Sam, primary, Tap, William D., primary, Takebe, Naoko, primary, Qin, Li-Xuan, primary, and Schwartz, Gary K., primary

Published
2023
Full Text
View/download PDF

119. Figure S1 from Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations

Author

Suehara, Yoshiyuki, primary, Alex, Deepu, primary, Bowman, Anita, primary, Middha, Sumit, primary, Zehir, Ahmet, primary, Chakravarty, Debyani, primary, Wang, Lu, primary, Jour, George, primary, Nafa, Khedoudja, primary, Hayashi, Takuo, primary, Jungbluth, Achim A., primary, Frosina, Denise, primary, Slotkin, Emily, primary, Shukla, Neerav, primary, Meyers, Paul, primary, Healey, John H., primary, Hameed, Meera, primary, and Ladanyi, Marc, primary

Published
2023
Full Text
View/download PDF

120. Supplementary Tables from Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations

Author

Suehara, Yoshiyuki, primary, Alex, Deepu, primary, Bowman, Anita, primary, Middha, Sumit, primary, Zehir, Ahmet, primary, Chakravarty, Debyani, primary, Wang, Lu, primary, Jour, George, primary, Nafa, Khedoudja, primary, Hayashi, Takuo, primary, Jungbluth, Achim A., primary, Frosina, Denise, primary, Slotkin, Emily, primary, Shukla, Neerav, primary, Meyers, Paul, primary, Healey, John H., primary, Hameed, Meera, primary, and Ladanyi, Marc, primary

Published
2023
Full Text
View/download PDF

122. Distinct IDH1/2-associated methylation profile and enrichment of TP53 and TERT mutations distinguish dedifferentiated chondrosarcoma from conventional chondrosarcoma

Author

Dermawan, Josephine Kam Tai, primary, Nafa, Khedoudja, additional, Mohanty, Abhinita, additional, Xu, Yingjuan, additional, Rijo, Ivelise, additional, Casanova, Jacklyn, additional, Villafania, Liliana, additional, Benhamida, Jamal, additional, Kelly, Ciara M., additional, Tap, William D., additional, Boland, Patrick, additional, Fabbri, Nicola, additional, Healey, John H., additional, Ladanyi, Marc, additional, Lu, Chao, additional, and Hameed, Meera R., additional

Published
2023
Full Text
View/download PDF

123. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Author

Tap, William D, Jones, Robin L, Van Tine, Brian A, Chmielowski, Bartosz, Elias, Anthony D, Adkins, Douglas, Agulnik, Mark, Cooney, Matthew M, Livingston, Michael B, Pennock, Gregory, Hameed, Meera R, Shah, Gaurav D, Qin, Amy, Shahir, Ashwin, Cronier, Damien M, Ilaria, Robert, Jr, Conti, Ilaria, Cosaert, Jan, and Schwartz, Gary K

Published
2016
Full Text
View/download PDF

124. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape

Author

Lu, Chao, Jain, Siddhant U., Hoelper, Dominik, Bechet, Denise, Molden, Rosalynn C., Ran, Leili, Murphy, Devan, Venneti, Sriram, Hameed, Meera, Pawel, Bruce R., Wunder, Jay S., Dickson, Brendan C., Lundgren, Stefan M., Jani, Krupa S., De Jay, Nicolas, Papillon-Cavanagh, Simon, Andrulis, Irene L., Sawyer, Sarah L., Grynspan, David, Turcotte, Robert E., Nadaf, Javad, Fahiminiyah, Somayyeh, Muir, Tom W., Majewski, Jacek, Thompson, Craig B., Chi, Ping, Garcia, Benjamin A., Allis, C. David, Jabado, Nada, and Lewis, Peter W.

Published
2016

126. Dual‐mode security authentication of SrAl2O4:Eu,Dy phosphor encapsulated in electrospun cellulose acetate nanofibrous films.

Author

El‐Newehy, Mohamed, El‐Hamshary, Hany, and Abdul Hameed, Meera Moydeen

Abstract

Photochromic inks have been an attractive authentication strategy to improve the anti‐counterfeiting efficiency of commercial products. However, recent reports have shown significant disadvantages with photochromic inks, including poor durability and high cost. In this context, we developed novel photochromic nanofibres for advanced anti‐counterfeiting applications. Lanthanide‐doped strontium aluminate (LdSA) nanoparticles (NPs) were prepared and immobilized into electrospun cellulose acetate nanofibres (CANF). Authentication materials immobilized with inorganic photochromic agents can warranty durability and photostability. Therefore, the ultraviolet‐stimulated photochromism of LdSA‐encapsulated cellulose acetate nanofibres (LdSA@CANF) demonstrated high reversibility and photostability. A broad range of cellulose acetate nanofibres with unique emission characteristics was developed when applying different ratios of LdSA NPs. LdSA@CANF appeared colourless under visible daylight, whereas a green emission was monitored under ultraviolet‐light illumination. The shape and chemical content of the photochromic fibrous films were examined using various analytical techniques. The mechanical characteristics of LdSA@CANF‐coated paper were investigated. The emission wavelength was detected at 514 nm to designate green colour, whereas the excitation wavelength was detected at 369 nm to indicate transparency. The prepared cellulose acetate nanofibrous film can be described as an efficient strategy for the anti‐counterfeiting of commercialized items. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

127. Datasets for reporting of soft‐tissue sarcoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Author

Dei Tos, Angelo Paolo, primary, Webster, Fleur, additional, Agaimy, Abbas, additional, Bovée, Judith, additional, Dickson, Brendan, additional, Doyle, Leona, additional, Dry, Sarah, additional, Gronchi, Alessandro, additional, Hameed, Meera, additional, Hemmings, Chris, additional, Liegl‐Atzwanger, Bernadette, additional, Thway, Khin, additional, Wagner, Andrew J, additional, Wang, Jian, additional, Yoshida, Akihiko, additional, and Fletcher, Christopher, additional

Published
2023
Full Text
View/download PDF

128. Current Laboratory Testing Practices for Assessment of ERBB2/HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma

Author

Hagemann, Ian S., primary, Bridge, Julia A., additional, Tafe, Laura J., additional, Hameed, Meera R., additional, Moncur, Joel T., additional, Bellizzi, Andrew M., additional, Dolan, Michelle, additional, Vasalos, Patricia, additional, Kane, Megan E., additional, Souers, Rhona J., additional, and Yemelyanova, Anna, additional

Published
2022
Full Text
View/download PDF

130. Deep Learning–Based Objective and Reproducible Osteosarcoma Chemotherapy Response Assessment and Outcome Prediction

Author

Ho, David J., primary, Agaram, Narasimhan P., additional, Jean, Marc-Henri, additional, Suser, Stephanie D., additional, Chu, Cynthia, additional, Vanderbilt, Chad M., additional, Meyers, Paul A., additional, Wexler, Leonard H., additional, Healey, John H., additional, Fuchs, Thomas J., additional, and Hameed, Meera R., additional

Published
2022
Full Text
View/download PDF

131. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Author

Zehir, Ahmet, Benayed, Ryma, Shah, Ronak H, Syed, Aijazuddin, Middha, Sumit, Kim, Hyunjae R, Srinivasan, Preethi, Gao, Jianjiong, Chakravarty, Debyani, Devlin, Sean M, Hellmann, Matthew D, Barron, David A, Schram, Alison M, Hameed, Meera, Dogan, Snjezana, Ross, Dara S, Hechtman, Jaclyn F, DeLair, Deborah F, Yao, JinJuan, Mandelker, Diana L, Cheng, Donavan T, Chandramohan, Raghu, Mohanty, Abhinita S, Ptashkin, Ryan N, Jayakumaran, Gowtham, Prasad, Meera, Syed, Mustafa H, Rema, Anoop Balakrishnan, Liu, Zhen Y, Nafa, Khedoudja, Borsu, Laetitia, Sadowska, Justyna, Casanova, Jacklyn, Bacares, Ruben, Kiecka, Iwona J, Razumova, Anna, Son, Julie B, Stewart, Lisa, Baldi, Tessara, Mullaney, Kerry A, Al-Ahmadie, Hikmat, Vakiani, Efsevia, Abeshouse, Adam A, Penson, Alexander V, Jonsson, Philip, Camacho, Niedzica, Chang, Matthew T, Won, Helen H, Gross, Benjamin E, Kundra, Ritika, Heins, Zachary J, Chen, Hsiao-Wei, Phillips, Sarah, Zhang, Hongxin, Wang, Jiaojiao, Ochoa, Angelica, Wills, Jonathan, Eubank, Michael, Thomas, Stacy B, Gardos, Stuart M, Reales, Dalicia N, Galle, Jesse, Durany, Robert, Cambria, Roy, Abida, Wassim, Cercek, Andrea, Feldman, Darren R, Gounder, Mrinal M, Hakimi, A Ari, Harding, James J, Iyer, Gopa, Janjigian, Yelena Y, Jordan, Emmet J, Kelly, Ciara M, Lowery, Maeve A, Morris, Luc G T, Omuro, Antonio M, Raj, Nitya, Razavi, Pedram, Shoushtari, Alexander N, Shukla, Neerav, Soumerai, Tara E, Varghese, Anna M, Yaeger, Rona, Coleman, Jonathan, Bochner, Bernard, Riely, Gregory J, Saltz, Leonard B, Scher, Howard I, Sabbatini, Paul J, Robson, Mark E, Klimstra, David S, Taylor, Barry S, Baselga, Jose, Schultz, Nikolaus, Hyman, David M, Arcila, Maria E, Solit, David B, Ladanyi, Marc, and Berger, Michael F

Subjects
Cancer -- Genetic aspects -- Research, Gene mutation -- Research, Cancer metastasis -- Genetic aspects -- Development and progression, Biological sciences, Health
Abstract

Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically defined tumor types, coupled with an expanding portfolio of molecularly targeted therapies, demands flexible and comprehensive approaches to profile clinically relevant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which we have compiled tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer and available pathological and clinical annotations. Using these data, we identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types. Patients were enrolled on genomically matched clinical trials at a rate of 11%. To enable discovery of novel biomarkers and deeper investigation into rare alterations and tumor types, all results are publicly accessible., Author(s): Ahmet Zehir [1]; Ryma Benayed [1]; Ronak H Shah [1]; Aijazuddin Syed [1]; Sumit Middha [1]; Hyunjae R Kim [1]; Preethi Srinivasan [1]; Jianjiong Gao [2]; Debyani Chakravarty [2]; [...]

Published
2017
Full Text
View/download PDF

135. Abstract A028: Growth factor signaling and kinase inhibitors regulate oncogenesis in desmoid fibromatosis by modulating activity of the beta-catenin transcription target ABL1

Author

Hu, Jia, primary, Villano, Anthony, additional, O'Connor, Rachael, additional, Rozenberg, Yuliy, additional, Venkatesh, Alankrta, additional, Gounder, Mrinal, additional, Socci, Nicholas, additional, Singer, Samuel, additional, Hameed, Meera, additional, and Crago, Aimee M., additional

Published
2022
Full Text
View/download PDF

136. Abstract PR012: Targeted sequencing of 2,138 bone and soft tissue sarcomas reveals commonly altered pathways, subtype-independent genetic clusters, and potential therapeutic targets

Author

Nacev, Benjamin A., primary, Sanchez-Vega, Francisco, additional, Smith, Shaleigh, additional, Antonescu, Cristina, additional, Rosenbaum, Evan, additional, Shi, Hongyu, additional, Tang, Cerise, additional, Socci, Nicholas, additional, Rana, Satshil, additional, Gularte-Merida, Rodrigo, additional, Zehir, Ahmet, additional, Gounder, Mrinal, additional, Bowler, Timothy, additional, Luthra, Anisha, additional, Jadeja, Bhumika, additional, Okada, Azusa, additional, Strong, Jonathan, additional, Stoller, Jake, additional, Chan, Jason, additional, Chi, Ping, additional, D'Angelo, Sandra, additional, Dickson, Mark, additional, Kelly, Ciara, additional, Keohan, Mary Louise, additional, Movva, Sujana, additional, Thornton, Katherine, additional, Meyers, Paul, additional, Wexler, Leonard, additional, Slotkin, Emily, additional, Bender, Julia Glade, additional, Shukla, Neerav, additional, Hensley, Martee, additional, Healey, John, additional, La Quaglia, Michael, additional, Alektiar, Kaled, additional, Crago, Aimee, additional, Yoon, Sam, additional, Untch, Brian, additional, Chiang, Sarah, additional, Agaram, Narasimhan, additional, Hameed, Meera, additional, Berger, Michael, additional, Solit, David, additional, Schultz, Nikolaus, additional, Ladanyi, Marc, additional, Singer, Samuel, additional, and Tap, William, additional

Published
2022
Full Text
View/download PDF

137. Abstract B023: Prospective clinical genomic profiling of ewing sarcoma: ERF and FGFR1 mutations as recurrent secondary alterations of potential biological and therapeutic relevance

Author

Elkrief, Arielle, primary, Ogura, Koichi, additional, Bowman, Anita S., additional, Koche, Richard P., additional, Benayed, Ryma, additional, Mauguen, Audrey, additional, Mattar, Marissa S., additional, Khodos, Inna, additional, de Stanchina, Elisa, additional, Meyers, Paul A., additional, Healey, John H., additional, Tap, William D., additional, Shukla, Neerav, additional, Hameed, Meera, additional, Zehir, Ahmet, additional, Sawyers, Charles, additional, Bose, Rohit, additional, Slotkin, Emily, additional, and Ladanyi, Marc, additional

Published
2022
Full Text
View/download PDF

138. Abstract B022: Subclonal somatic copy number alterations emerge and dominate in relapsed/refractory osteosarcoma

Author

Kinnaman, Michael D., primary, Zaccaria, Simone, additional, Makohon-Moore, Alvin, additional, Gundem, Gunes, additional, Ossa, Juan E. Arango, additional, Bouvier, Nancy, additional, Dela Cruz, Filemon S., additional, Hameed, Meera, additional, Bender, Julia Lynne Glade, additional, Tap, William D., additional, Meyers, Paul, additional, Papaemmanuil, Elli, additional, Kung, Andrew, additional, and Iacobuzio-Donahue, Christine A., additional

Published
2022
Full Text
View/download PDF

141. Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma

Author

Ortiz, Michael V., Magnan, Heather, Slotkin, Emily K., Ambati, Srikanth R., Chou, Alexander J., Wexler, Leonard H., Meyers, Paul A., Walsh, Michael F., Heaton, Todd, Girardi, Leonard N., Wolden, Suzanne L., Price, Anita P., Kennedy, Jennifer A., Zehir, Ahmet, Hameed, Meera, Berger, Michael F., Kentsis, Alex, and Shukla, Neerav

Published
2017
Full Text
View/download PDF

142. High Performance of Nanostructured Cu 2 O-Based Photodetectors Grown on a Ti/Mo Metallic Substrate.

Author

Abdelmoneim, Alhoda, Abdel-wahab, Mohamed Sh., Lee, June Key, Abdul Hameed, Meera Moydeen, Thamer, Badr M., Al-Enizi, Abdullah M., Alkhalifah, Rayana Ibrahim, and Tawfik, Wael Z.

Subjects
COPPER, PHOTODETECTORS, QUANTUM efficiency, LIGHT transmission, THIN films, METALLIC films
Abstract

In this work, cuprous oxide (Cu2O) thin films were prepared using a simplistic sputtering technique. The films were grown on both traditional fluorine-doped tin oxide (FTO) and Ti-metallic substrates. X-ray diffraction applied for investigation of the crystal structure proved that the Cu2O layer acquires the cubic structure with a (111) main peak at 2θ of 36.46°. The optical absorption and transmission were detected through the utilization of a UV-Vis spectrophotometer, and the optical bandgap for the Cu2O layer was determined to be ~2.15 eV using Tauc's equation. XPS and scanning electron microscopy were also performed for chemical structure and morphological investigation, respectively. The optoelectronic behaviors for the prepared samples were carried out using a Keithley source meter; the photocurrent density was measured in a range of applied voltage between −1 and 1 volt under the illumination of a xenon lamp with a power density of 100 mWcm−2. External quantum efficiency, sensitivity, responsivity, and detectivity were computed using proprietary models based on the experimental data. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

143. Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas: Guideline from the College of American Pathologists in collaboration with the American Association of Neuropathologists, Association for Molecular Pathology, and Society for Neuro-Oncology

Author

Brat, Daniel J., Aldape, Kenneth, Bridge, Julia A., Canoll, Peter, Colman, Howard, Hameed, Meera R., Harris, Brent T., Hattab, Eyas M., Huse, Jason T., Jenkins, Robert B., Lopez-Terrada, Dolores H., McDonald, William C., Rodriguez, Fausto J., Souter, Lesley H., Colasacco, Carol, Thomas, Nicole E., Hawks Yount, Michelle, van den Bent, Martin J., Perry, Arie, and Neurology

Subjects
Adult, Pathologists, Molecular Diagnostic Techniques, Receptor, ErbB-2, Biomarkers, Tumor, Humans, Glioma, Child, Article
Abstract

CONTEXT. –: The diagnosis and clinical management of patients with diffuse gliomas have evolved rapidly over the past decade with the emergence of molecular biomarkers that are used to classify, stratify risk and predict treatment response for optimal clinical care. OBJECTIVE. –: To develop evidence-based recommendations for informing molecular biomarker testing for pediatric and adult patients with diffuse gliomas and provide guidance for appropriate laboratory test and biomarker selection for optimal diagnosis, risk stratification and prediction. DESIGN. –: The College of American Pathologists convened an expert panel to perform a systematic review of the literature and develop recommendations. A systematic review of literature was conducted to address the overarching question, “What ancillary tests are needed to classify diffuse gliomas and sufficiently inform the clinical management of patients?” Recommendations were derived from quality of evidence, open comment feedback, and expert panel consensus. RESULTS. –: Thirteen recommendations and 3 good practice statements were established to guide pathologists and treating physicians on the most appropriate methods and molecular biomarkers to include in laboratory testing to inform clinical management of patients with diffuse gliomas. CONCLUSIONS. –: Evidence-based incorporation of laboratory results from molecular biomarker testing into integrated diagnoses of diffuse gliomas provides reproducible and clinically meaningful information for patient management.

Published
2022

147. Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma.

Author

Kinnaman, Michael David, primary, Zaccaria, Simone, additional, Makohon-Moore, Alvin, additional, Gundem, Gunes, additional, Arango Ossa, Juan E., additional, Bouvier, Nancy, additional, Dela Cruz, Filemon S., additional, Hameed, Meera, additional, Glade Bender, Julia Lynne, additional, Tap, William D., additional, Meyers, Paul A., additional, Papaemmanuil, Elli, additional, Kung, Andrew, additional, and Iacobuzio-Donahue, Christine A, additional

Published
2022
Full Text
View/download PDF

148. Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data

Author

Vanderbilt, Chad M., primary, Bowman, Anita S., additional, Middha, Sumit, additional, Petrova-Drus, Kseniya, additional, Tang, Yi-Wei, additional, Chen, Xin, additional, Wang, Youxiang, additional, Chang, Jason, additional, Rekhtman, Natasha, additional, Busam, Klaus J., additional, Gupta, Sounak, additional, Hameed, Meera, additional, Arcila, Maria E., additional, Ladanyi, Marc, additional, Berger, Michael F., additional, Dogan, Snjezana, additional, and Zehir, Ahmet, additional

Published
2022
Full Text
View/download PDF

149. Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors

Author

Ramkissoon, Shakti H., primary, Fernandes, Helen, additional, Lopez-Terrada, Dolores H., additional, Hameed, Meera R., additional, Trembath, Dimitri G., additional, Bridge, Julia A., additional, Lindeman, Neal I., additional, Souers, Rhona J., additional, Vasalos, Patricia, additional, Brat, Daniel J., additional, and Moncur, Joel T., additional

Published
2022
Full Text
View/download PDF

150. Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas:Guideline from the College of American Pathologists in Collaboration with the American Association of Neuropathologists, Association for Molecular Pathology, and Society for Neuro-Oncology

Author

Brat, Daniel J., Aldape, Kenneth, Bridge, Julia A., Canoll, Peter, Colman, Howard, Hameed, Meera R., Harris, Brent T., Hattab, Eyas M., Huse, Jason T., Jenkins, Robert B., Lopez-Terrada, Dolores H., McDonald, William C., Rodriguez, Fausto J., Souter, Lesley H., Colasacco, Carol, Thomas, Nicole E., Hawks Yount, Michelle, van den Bent, Martin J., Perry, Arie, Brat, Daniel J., Aldape, Kenneth, Bridge, Julia A., Canoll, Peter, Colman, Howard, Hameed, Meera R., Harris, Brent T., Hattab, Eyas M., Huse, Jason T., Jenkins, Robert B., Lopez-Terrada, Dolores H., McDonald, William C., Rodriguez, Fausto J., Souter, Lesley H., Colasacco, Carol, Thomas, Nicole E., Hawks Yount, Michelle, van den Bent, Martin J., and Perry, Arie

Abstract

Context.—The diagnosis and clinical management of patients with diffuse gliomas (DGs) have evolved rapidly over the past decade with the emergence of molecular biomarkers that are used to classify, stratify risk, and predict treatment response for optimal clinical care. Objective.—To develop evidence-based recommendations for informing molecular biomarker testing for pediatric and adult patients with DGs and provide guidance for appropriate laboratory test and biomarker selection for optimal diagnosis, risk stratification, and prediction. Design.—The College of American Pathologists convened an expert panel to perform a systematic review of the literature and develop recommendations. A systematic review of literature was conducted to address the overarching question, ‘‘What ancillary tests are needed to classify DGs and sufficiently inform the clinical management of patients?’’ Recommendations were derived from quality of evidence, open comment feedback, and expert panel consensus. Results.—Thirteen recommendations and 3 good practice statements were established to guide pathologists and treating physicians on the most appropriate methods and molecular biomarkers to include in laboratory testing to inform clinical management of patients with DGs. Conclusions.—Evidence-based incorporation of laboratory results from molecular biomarker testing into integrated diagnoses of DGs provides reproducible and clinically meaningful information for patient management.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results